BRPI0716455A8 - desenvolvimento de componentes de vacina do vírus da dengue - Google Patents

desenvolvimento de componentes de vacina do vírus da dengue

Info

Publication number
BRPI0716455A8
BRPI0716455A8 BRPI0716455A BRPI0716455A BRPI0716455A8 BR PI0716455 A8 BRPI0716455 A8 BR PI0716455A8 BR PI0716455 A BRPI0716455 A BR PI0716455A BR PI0716455 A BRPI0716455 A BR PI0716455A BR PI0716455 A8 BRPI0716455 A8 BR PI0716455A8
Authority
BR
Brazil
Prior art keywords
dengue virus
utr
mutation
development
vaccine components
Prior art date
Application number
BRPI0716455A
Other languages
English (en)
Inventor
R Murphy Brian
e blaney Joseph
S Whitehead Stephen
Original Assignee
Government Of The Us Secretary Of The Department Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government Of The Us Secretary Of The Department Of Health And Human Services filed Critical Government Of The Us Secretary Of The Department Of Health And Human Services
Priority to BR122020023372-9A priority Critical patent/BR122020023372B1/pt
Publication of BRPI0716455A2 publication Critical patent/BRPI0716455A2/pt
Publication of BRPI0716455A8 publication Critical patent/BRPI0716455A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
    • C07K14/1825—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

desenvolvimento de componentes de vacina do vírus da dengue a invenção refere-se a um vírus da dengue ou vírus da dengue quimérico que con-5 tém uma mutação na região não transcrita 3' (3'-utr) compreendendo uma mutação 630 que remove a estrutura homóloga tl-2 em cada um dos sorotipos de vírus da dengue 1, 2, 3, ou 4 e nucleotídeos adicionais à mutação 630 deletados da 3'-utr que remove a se-quência na direção 5' até o limite 5' da estrutura homóloga tl-3 em cada um dos sorotipos de vírus da dengue 1, 2, 3, ou 4, ou uma recolocação da 3'-utr de um vírus da dengue de um primeiro sorotipo com a 3'-utr de um vírus da dengue de um segundo sorotipo, opcio- nalmente contendo a mutação 630 e nucleotídeos adicionais à mutação a30 deletados da 3'-utr; e composições imunogênicas, métodos de induzir uma resposta imunogênica e mé-todos de produzir um vírus da dengue ou vírus da dengue quimérico.
BRPI0716455A 2006-08-15 2007-08-15 desenvolvimento de componentes de vacina do vírus da dengue BRPI0716455A8 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122020023372-9A BR122020023372B1 (pt) 2006-08-15 2007-08-15 Vírus da dengue do tipo 3 (den3) atenuado e composição imunogênica

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83772306P 2006-08-15 2006-08-15
PCT/US2007/076004 WO2008022196A2 (en) 2006-08-15 2007-08-15 Development of dengue virus vaccine components

Publications (2)

Publication Number Publication Date
BRPI0716455A2 BRPI0716455A2 (pt) 2014-03-04
BRPI0716455A8 true BRPI0716455A8 (pt) 2019-01-15

Family

ID=39083099

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122020023372-9A BR122020023372B1 (pt) 2006-08-15 2007-08-15 Vírus da dengue do tipo 3 (den3) atenuado e composição imunogênica
BRPI0716455A BRPI0716455A8 (pt) 2006-08-15 2007-08-15 desenvolvimento de componentes de vacina do vírus da dengue

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR122020023372-9A BR122020023372B1 (pt) 2006-08-15 2007-08-15 Vírus da dengue do tipo 3 (den3) atenuado e composição imunogênica

Country Status (15)

Country Link
US (8) US8337860B2 (pt)
EP (2) EP2589602B1 (pt)
CN (2) CN103602689B (pt)
AU (1) AU2007285929B2 (pt)
BR (2) BR122020023372B1 (pt)
CA (2) CA3004991C (pt)
CY (1) CY1118003T1 (pt)
DK (2) DK2054428T3 (pt)
ES (1) ES2585553T3 (pt)
HU (1) HUE029333T2 (pt)
LT (1) LT2589602T (pt)
PL (1) PL2589602T3 (pt)
PT (1) PT2589602T (pt)
SI (1) SI2589602T1 (pt)
WO (1) WO2008022196A2 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2472468C (en) * 2002-01-10 2015-11-24 Alexander G. Pletnev Construction of west nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by west nile virus
BRPI0309631B1 (pt) 2002-05-03 2021-07-20 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Composição imunogênica tetravalente compreendendo vírus atenuado contra dengue e vacina tetravalente compreendendo a dita composição
DK2054428T3 (da) 2006-08-15 2013-08-26 Government Of The U S A As Repr By The Secretary Dept Of Health & Human Services The Nat Inst Of Hea Udvikling af bestanddele til denque-virus-vaccine
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
MY184428A (en) 2009-06-01 2021-04-01 Inviragen Inc Compositions and methods for administration of vaccines against dengue virus
US8895028B2 (en) 2012-07-20 2014-11-25 Arbovax, Inc. Methods and compositions for dengue virus 3 (DV3) infectious clone
JP2016504315A (ja) 2012-12-14 2016-02-12 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. 三価デングウイルス製剤に関する組成物、投与方法および使用
EP4183411A1 (en) * 2013-03-15 2023-05-24 Takeda Vaccines, Inc. Compositions and methods for dengue virus chimeric constructs in vaccines
WO2014204892A1 (en) 2013-06-21 2014-12-24 Merck Sharp & Dohme Corp. Dengue virus vaccine compositions and methods of use thereof
MY179251A (en) * 2014-11-02 2020-11-02 Univ North Carolina Chapel Hill Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development
MY192543A (en) * 2014-12-22 2022-08-26 Merck Sharp & Dohme Dengue virus vaccine compositions and methods of use thereof
EP3316897A4 (en) 2015-07-02 2019-03-13 Primevax Immuno-Oncology, Inc. COMPOSITIONS AND METHODS FOR COMBINATION THERAPY WITH DENGUE VIRUS AND DENDRITIC CELLS
MX2018003757A (es) 2015-09-26 2018-09-21 Primevax Immuno Oncology Inc Composiciones y metodos para producir celulas dendriticas.
EP3355916A4 (en) * 2015-09-30 2018-08-29 Panacea Biotec Limited Stable live attenuated recombinant dengue vaccine
WO2017156511A1 (en) 2016-03-11 2017-09-14 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Live attenuated zika virus vaccine
CA3082779A1 (en) 2016-11-16 2018-05-24 PrimeVax Immuno-Oncology, Inc. Combination immunotherapies for treatment of cancer
WO2018129202A1 (en) * 2017-01-04 2018-07-12 PrimeVax Immuno-Oncology, Inc. Compositions and methods for therapy with dengue virus
WO2018129160A1 (en) 2017-01-06 2018-07-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Live attenuated flavivirus vaccines and methods of using and making same
CN110381993B (zh) * 2017-02-14 2024-03-29 得克萨斯大学体系董事会 具有3’utr缺失的活减毒寨卡病毒、含有所述病毒的疫苗及其用途
US10240130B2 (en) 2017-02-15 2019-03-26 The Board Of Regents Of The University Of Texas System CDNA clone-launched platform for high-yield production of inactivated zika virus
CN117752780A (zh) 2017-12-07 2024-03-26 默沙东有限责任公司 登革病毒疫苗组合物的制剂
EP4013451A1 (en) 2019-08-16 2022-06-22 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis a
EP4277641A1 (en) * 2021-02-26 2023-11-22 Duke University Compositions for and methods of improving gene therapy
WO2023161715A1 (en) * 2022-02-22 2023-08-31 Futr Bio Ltda. Next generation mrna vaccines

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184024B1 (en) * 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
BRPI0309631B1 (pt) 2002-05-03 2021-07-20 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Composição imunogênica tetravalente compreendendo vírus atenuado contra dengue e vacina tetravalente compreendendo a dita composição
EP1761277A1 (en) * 2004-06-14 2007-03-14 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES West nile viruses with mutations in the 3' terminal stem and loop secondary structure for use as live virus vaccines
DK2054428T3 (da) * 2006-08-15 2013-08-26 Government Of The U S A As Repr By The Secretary Dept Of Health & Human Services The Nat Inst Of Hea Udvikling af bestanddele til denque-virus-vaccine

Also Published As

Publication number Publication date
PL2589602T3 (pl) 2016-11-30
US20220251521A1 (en) 2022-08-11
LT2589602T (lt) 2016-10-10
EP2054428B1 (en) 2013-06-05
CA2661296A1 (en) 2008-02-21
US20200318083A1 (en) 2020-10-08
AU2007285929B2 (en) 2013-09-05
US20180171308A1 (en) 2018-06-21
DK2054428T3 (da) 2013-08-26
US20240084269A1 (en) 2024-03-14
CY1118003T1 (el) 2017-05-17
WO2008022196A2 (en) 2008-02-21
CA2661296C (en) 2018-06-26
DK2589602T3 (en) 2016-07-25
BR122020023372B1 (pt) 2021-11-30
US10160957B2 (en) 2018-12-25
US20190119654A1 (en) 2019-04-25
EP2589602A3 (en) 2013-10-09
EP2054428B9 (en) 2013-11-13
CN101657463B (zh) 2013-09-18
US11332722B2 (en) 2022-05-17
EP2054428A2 (en) 2009-05-06
US10724007B2 (en) 2020-07-28
CA3004991A1 (en) 2008-02-21
AU2007285929A2 (en) 2009-04-23
US9090873B2 (en) 2015-07-28
PT2589602T (pt) 2016-07-13
EP2589602B1 (en) 2016-04-06
US11746335B2 (en) 2023-09-05
BRPI0716455A2 (pt) 2014-03-04
USRE46042E1 (en) 2016-06-28
ES2585553T3 (es) 2016-10-06
WO2008022196A3 (en) 2009-03-12
US20100104598A1 (en) 2010-04-29
SI2589602T1 (sl) 2016-08-31
CN103602689A (zh) 2014-02-26
CN101657463A (zh) 2010-02-24
AU2007285929A1 (en) 2008-02-21
US20130089567A1 (en) 2013-04-11
CA3004991C (en) 2022-08-30
CN103602689B (zh) 2016-08-24
HUE029333T2 (en) 2017-03-28
EP2589602A2 (en) 2013-05-08
US8337860B2 (en) 2012-12-25

Similar Documents

Publication Publication Date Title
BRPI0716455A8 (pt) desenvolvimento de componentes de vacina do vírus da dengue
AR069882A1 (es) Circovirus porcino, molecula de acido nucleico aislada que lo codifica, composicion inmunogenica que lo comprende, vector que comprende por lo menos una molecula de acido nucleico exogena que codifica una proteina de circovirus porcino y metodos para inmunizar un cerdo contra la infeccion virica o e
BRPI0309631A8 (pt) vacina tetravalente da dengue contendo uma trivial deleção de 30 nucleotídeos na utr-31' dos tipos de dengue 1,2,3 e 4, ou de vírus antigênicos quiméricos da dengue 1,2,3 e 4
PE20140646A1 (es) Vacuna de virus de dengue inactivado
PH12015500773A1 (en) Methods and compositions for live attenuated viruses
BR112018068342A2 (pt) vacina de vírus zika vivo atenuado
MY150613A (en) Stabilizer and vaccine composition comprising one or more live attenuated flaviviruses
JP2010511022A5 (pt)
TW200732476A (en) Functional influenza virus like particles (VLPs)
MX2009004223A (es) Protocolo de inmunizacion contra los 4 serotipos del dengue.
BRPI0814899A2 (pt) Composição, vacina, metodo para amenizar um ou mais sintomas associados à infecção com o virus da influenza em um individuo e método para reduzir a probabilidade de infecção com o virus da influeza em um individuo"
ATE479440T1 (de) Virusstämme und zusammensetzungen des prrs- syndroms (porcine reproductive und respiratory syndrome) von schweinen
AR044696A1 (es) Composicion de vacunas
BR112015001313A2 (pt) composições de vacina
ME01140B (me) Virus goveđe virusne dijareje s modifikovanim erns proteinom
AR072302A1 (es) Pestivirus atenuados. composicion inmunogenica. metodo.
BRPI0312173B8 (pt) vetor e processo para a preparação de partículas infecciosas de vírus do sarampo
NZ618158A (en) Compositions and methods for administration of vaccines against dengue virus
BR112018068642A2 (pt) composição e uso de composição
PH12016500761A1 (en) Infant formulas containing a 2-fucosylated oligosaccharide for treatment or prevention of influenza infection
BR112019006802A2 (pt) compostos e métodos para diagnóstico e tratamento de infecções virais
BR112014017141A2 (pt) método de tratamento de diabetes usando-se apolipoproteína a-iv não glicosilada
BRPI0516542A (pt) composição de vacina eficaz na prevenção ou melhora de infecção pelo vìrus da influenza aviária; método para prevenir ou melhorar a eclosão de infecção pelo vìrus da influenza aviária
BR112015031226A2 (pt) Composição de vacina, e, uso da composição de vacina
AR059005A1 (es) Virus quimericos del dengue

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]